Gene delivery and gene therapy with herpes simplex virus-based vectors

Gene

Volumn 264, Issue 1, 2001, Pages 1-9

  Latchman, David S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene delivery; Gene therapy; Herpes simplex virus; Neurological disease; Virus vectors

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LIPOSOME; PLASMID DNA; VIRUS VECTOR;

BRAIN NERVE CELL; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ENCEPHALITIS; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENOME; HUMAN; HUMAN HERPESVIRUS 6; INTERMETHOD COMPARISON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRANSGENE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; SIMPLEXVIRUS;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0035819551     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(01)00322-5     Document Type: Review

References (59)

1. Construction and characterisation of a herpes simplex virus type I mutant unable to transduce immediate-early gene expression
2. Overexpression of heat shock protein 70 protects neuronal cells against both thermal and ischaemic stress but with different efficiencies
3. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts
4. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
5. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or ischaemic stress
6. Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants
7. Herpes simplex virus based vectors
8. Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors
9. Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors
10. Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry
11. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene antisense transcript by in situ hybridization
12. A latent nonpathogenic HSV-1 derived vector stably expresses β galactosidase in mouse neurons
13. In vivo deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter
14. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydoxylase
15. In vivo expression of βgalactosidase in hippocampal neurons by HSV mediated gene transfer
16. Gene transfer to neurons using herpes simplex virus-based vectors
17. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa
18. Prospects for gene therapy in Parkinson's Disease
19. Human gene therapy
20. Gene therapy scores against cancer
21. Herpes simplex virus Vmw65-octamer binding protein interaction: A paradigm for combinatorial control of transcription
22. A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats
23. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
24. β-Galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus infected mouse
25. Herpes Simplex virus latent RNA (Lat) is not required for latent infection in the mouse
26. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease
27. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5
28. Herpes simplex virus type 1 vector mediated gene transfer to muscle
29. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
30. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders
31. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS
32. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease
33. Molecular biology of herpes simplex virus latency
34. Viral vectors and Parkinson's disease
35. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease
36. Long term promoter activity during herpes simplex virus latency
37. Ex vivo Hepatic gene transfer in mouse using a defective herpes simplex virus1 vector
38. Herpes Simplex Virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17 + between immediate-early gene 1 and the 'a' sequence
39. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-Cyclohydrolase I in a rat model of Parkinson's Disease
40. Pathways of viral gene expression during acute neuronal infection with HSV-1
41. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs
42. Human gene therapy comes of age
43. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
44. Fetal nigral transplantation as a therapy for Parkinson's disease
45. Herpes simplex virus mediated human hypoxanthineguanine phosphoribosyl transferase gene transfer into neuronal cells
46. Development and optimisation of herpes simplex virus vectors for multiple long term gene delivery to the peripheral nervous system
47. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
48. An inquiry into the mechanisms of herpes simplex virus latency
49. Herpes simplex virus type 1 ICP27 is an essential regulatory protein
50. Transplantation of genetically modified non-neuronal cells in the central nervous system
51. Bcl-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor
52. RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons
53. Equine herpes virus 1 gene 12 can substitute for Vmw65 in the growth of herpes simplex virus 1 (HSV1) allowing the generation of optimised cell lines for the propagation of vectors with multiple immediate-early gene defects
54. Direct injection of plasmid DNA into the brain
55. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector
56. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1
57. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
58. Trigeminal ganglion neurons are protected by the heat shock proteins hsp70 and hsp90 from thermal stress but not from programmed cell death following NGF withdrawal